Review





Similar Products

94
ATCC p aeruginosa strain serotype iats o11
Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. <t>aeruginosa</t> , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.
P Aeruginosa Strain Serotype Iats O11, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p aeruginosa strain serotype iats o11/product/ATCC
Average 94 stars, based on 1 article reviews
p aeruginosa strain serotype iats o11 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

90
Millipore hoechst 33358
Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. <t>aeruginosa</t> , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.
Hoechst 33358, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hoechst 33358/product/Millipore
Average 90 stars, based on 1 article reviews
hoechst 33358 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Millipore hoechst 33358 (1∶5000
Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. <t>aeruginosa</t> , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.
Hoechst 33358 (1∶5000, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hoechst 33358 (1∶5000/product/Millipore
Average 90 stars, based on 1 article reviews
hoechst 33358 (1∶5000 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Beyotime hoechst 33358
Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. <t>aeruginosa</t> , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.
Hoechst 33358, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hoechst 33358/product/Beyotime
Average 90 stars, based on 1 article reviews
hoechst 33358 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Thermo Fisher potassium hexacyanoferrate (ii) trihydrate #33358
Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. <t>aeruginosa</t> , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.
Potassium Hexacyanoferrate (Ii) Trihydrate #33358, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/potassium hexacyanoferrate (ii) trihydrate #33358/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
potassium hexacyanoferrate (ii) trihydrate #33358 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

90
Thermo Fisher hoechst 33358
Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. <t>aeruginosa</t> , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.
Hoechst 33358, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hoechst 33358/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
hoechst 33358 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. aeruginosa , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.

Journal: eBioMedicine

Article Title: Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia

doi: 10.1016/j.ebiom.2025.105926

Figure Lengend Snippet: Schematic representation and characterisation of CoMiX-Fc (a) and CoMiX-FHR1 (b) proteins. The dimerisation scaffold derived from the β-chain of C4BP is used to combine the targeting function of the scFv recognising P. aeruginosa , to either an Fc-region (CoMiX-Fc, a ) or the CCP3-5 domains of Factor H-related protein 1 (CoMiX-FHR1, b ). Both proteins were purified with protein G affinity columns for CoMiX-Fc and a Nickel column binding to the His-tag at the C-terminal end of CoMiX-FHR1. (c) SYPRO Ruby Staining: 3 μg of CoMiX-Fc and CoMiX-FHR1 proteins were loaded onto 4–15% SDS-PAGE gels and stained with SYPRO Ruby. (d) Western Blotting: Proteins, in non-reduced (NR) and reduced (R) conditions, from the SDS-PAGE gel were transferred to a low-fluorescence PVDF membrane and probed with specific fluorochrome-conjugated antibodies: anti-Fc AF647 for CoMiX-Fc and anti-His AF647 for CoMiX-FHR1. Protein bands from the two techniques were detected using an Amersham Typhoon scanner. The predicted molecular weight of CoMiX-Fc is approximately 122 kDa in normal conditions and 61 kDa when reduced, while CoMiX-FHR1 has a smaller size of around 107 kDa in normal conditions, and 53 kDa when reduced.

Article Snippet: P. aeruginosa strain serotype IATS O11 (33358TM), reference strain PAO1 (15692TM), and PAO1-GFP (15692GFPTM) were obtained from the American Type Culture Collection (ATCC, USA).

Techniques: Derivative Assay, Purification, Nickel Column, Binding Assay, Staining, SDS Page, Western Blot, Fluorescence, Membrane, Molecular Weight

Anti-Psl CoMiX bind specifically to P. aeruginosa , but not to other bacterial strains, with CoMiX-FHR1 competing with FH. The binding of anti- P. aeruginosa CoMiX, irrelevant anti- A. fumigatus CoMiX, and irrelevant anti- M. catarrhalis CoMiX to reference strain PAO1 (a) , clinical isolate IT 2 (b) , and Gram-bacterial strain M. catarrhalis (c) was analysed by whole-cell ELISA. Immobilised bacteria (1 × 10 7 CFU/mL) or bacterial lysate (20 μg/mL) were incubated with 10 μg/mL of CoMiX and irrelevant controls. Bound CoMiX was detected using specific antibodies: anti-His for CoMiX-FHR1 and anti-Fc for CoMiX-Fc. CoMiX targeting the second bacterial strain and the fungi were used as negative control. Data are presented as the mean values ± SEM. Results correspond to two-three pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗∗∗p < 0.0001. To investigate the competition between FH and CoMiX-FHR1, recombinant FH (20 μg/mL) and increasing concentrations of CoMiX-FHR1 (and CoMiX-Fc as control) were added to PAO1 bacteria. The binding of FH to bacterial cells was detected with the FH-specific monoclonal antibody OX-24 (d) . Data are presented as the mean values ± SEM. Results correspond to two-three pooled independent experiments (3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: it indicates significant differences for the binding of FH in absence versus presence of CoMiX-FHR1. ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Journal: eBioMedicine

Article Title: Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia

doi: 10.1016/j.ebiom.2025.105926

Figure Lengend Snippet: Anti-Psl CoMiX bind specifically to P. aeruginosa , but not to other bacterial strains, with CoMiX-FHR1 competing with FH. The binding of anti- P. aeruginosa CoMiX, irrelevant anti- A. fumigatus CoMiX, and irrelevant anti- M. catarrhalis CoMiX to reference strain PAO1 (a) , clinical isolate IT 2 (b) , and Gram-bacterial strain M. catarrhalis (c) was analysed by whole-cell ELISA. Immobilised bacteria (1 × 10 7 CFU/mL) or bacterial lysate (20 μg/mL) were incubated with 10 μg/mL of CoMiX and irrelevant controls. Bound CoMiX was detected using specific antibodies: anti-His for CoMiX-FHR1 and anti-Fc for CoMiX-Fc. CoMiX targeting the second bacterial strain and the fungi were used as negative control. Data are presented as the mean values ± SEM. Results correspond to two-three pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗∗∗p < 0.0001. To investigate the competition between FH and CoMiX-FHR1, recombinant FH (20 μg/mL) and increasing concentrations of CoMiX-FHR1 (and CoMiX-Fc as control) were added to PAO1 bacteria. The binding of FH to bacterial cells was detected with the FH-specific monoclonal antibody OX-24 (d) . Data are presented as the mean values ± SEM. Results correspond to two-three pooled independent experiments (3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: it indicates significant differences for the binding of FH in absence versus presence of CoMiX-FHR1. ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Article Snippet: P. aeruginosa strain serotype IATS O11 (33358TM), reference strain PAO1 (15692TM), and PAO1-GFP (15692GFPTM) were obtained from the American Type Culture Collection (ATCC, USA).

Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Bacteria, Incubation, Negative Control, Recombinant, Control

Anti-Psl CoMiX enhance C1q deposition (for CoMiX-Fc), C3b opsonisation and the formation of membrane attack complex (C5b9/MAC) on P. aeruginosa . Immobilised bacterial cells of the P. aeruginosa reference strain PAO1 and the clinical isolate IT 2 were incubated with 10 μg/mL of CoMiX, before the addition of either 2% (C3b) or 4% (C1q, C5b9/MAC) of normal human serum (NHS) or heat-inactivated human serum (ΔNHS) in GVB++ at 37 °C for 30 min. Complement deposition at the bacterial surface was measured by ELISA, using (a) an anti-human C1q mAb, (b) an anti-human C3/C3b/iC3b mAb, and (c) an anti-human C5b9 mAb, followed by an HRP-conjugated anti-mouse IgG mAb. Data are presented as the mean values ± SEM. Results correspond to three pooled independent experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. GFP-expressing PAO1 bacteria were incubated with 10% C5-deficient serum (C3b) or normal human serum (C5b9/MAC) at 37 °C for 1 h, in the presence or absence of 10 μg/mL of CoMiX. Bacteria were then incubated with either a goat anti-human C3b or goat anti-human C5b9 antibody, followed by a secondary AF647-conjugated anti-goat mAb. Once stained, bacteria were mounted onto an agarose gel pad, visualised on a confocal Leica Sp8 microscope (C3b), or on a wide field Axio observer microscope (C5b), and analysed by ImageJ to detect C3 cleavage product (C3b, iC3b, and C3c) deposition (d) or C5b9 deposition (e) . Two to four fields have been acquired for each conditions. Representative images of the deposition are presented here. Green = GFP-expressing PAO1, red = C3b or C5b9 deposition by anti-goat AF647. Scale bar = 5 μm; 10 μm.

Journal: eBioMedicine

Article Title: Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia

doi: 10.1016/j.ebiom.2025.105926

Figure Lengend Snippet: Anti-Psl CoMiX enhance C1q deposition (for CoMiX-Fc), C3b opsonisation and the formation of membrane attack complex (C5b9/MAC) on P. aeruginosa . Immobilised bacterial cells of the P. aeruginosa reference strain PAO1 and the clinical isolate IT 2 were incubated with 10 μg/mL of CoMiX, before the addition of either 2% (C3b) or 4% (C1q, C5b9/MAC) of normal human serum (NHS) or heat-inactivated human serum (ΔNHS) in GVB++ at 37 °C for 30 min. Complement deposition at the bacterial surface was measured by ELISA, using (a) an anti-human C1q mAb, (b) an anti-human C3/C3b/iC3b mAb, and (c) an anti-human C5b9 mAb, followed by an HRP-conjugated anti-mouse IgG mAb. Data are presented as the mean values ± SEM. Results correspond to three pooled independent experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. GFP-expressing PAO1 bacteria were incubated with 10% C5-deficient serum (C3b) or normal human serum (C5b9/MAC) at 37 °C for 1 h, in the presence or absence of 10 μg/mL of CoMiX. Bacteria were then incubated with either a goat anti-human C3b or goat anti-human C5b9 antibody, followed by a secondary AF647-conjugated anti-goat mAb. Once stained, bacteria were mounted onto an agarose gel pad, visualised on a confocal Leica Sp8 microscope (C3b), or on a wide field Axio observer microscope (C5b), and analysed by ImageJ to detect C3 cleavage product (C3b, iC3b, and C3c) deposition (d) or C5b9 deposition (e) . Two to four fields have been acquired for each conditions. Representative images of the deposition are presented here. Green = GFP-expressing PAO1, red = C3b or C5b9 deposition by anti-goat AF647. Scale bar = 5 μm; 10 μm.

Article Snippet: P. aeruginosa strain serotype IATS O11 (33358TM), reference strain PAO1 (15692TM), and PAO1-GFP (15692GFPTM) were obtained from the American Type Culture Collection (ATCC, USA).

Techniques: Membrane, Incubation, Enzyme-linked Immunosorbent Assay, Expressing, Bacteria, Staining, Agarose Gel Electrophoresis, Microscopy

CoMiX enhance complement-mediated killing of P. aeruginosa and display synergy with amikacin. (a) Bacterial reference strain PAO1, and clinical isolate IT 2 were incubated without serum (w/o NHS), with 10% normal human serum (NHS) or with 10% decomplemented serum (ΔNHS) in the presence or absence of 30 μg/mL CoMiX or irrelevant control for 2 h at 37 °C. Bacteria were plated and CFU were enumerated to assess bacterial viability. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. (b) A mutated PAO1 bacterial strain with a luminescence-based reporter system (PAO1-Lux) was used in the same protocol to monitor in real-time bacterial growth. The luminescence of bacteria (RLU) was measured after 2 h of incubation on a POLARStar Omega microplate reader, as it is known that luminescence of bacteria correlates well with its concentration. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗∗∗p < 0.0001. (c) The complement potency of mouse serum (MS) and decomplemented MS (ΔMS) was assessed using the same protocol as in a. Bacteria were plated and CFU were enumerated to assess bacterial viability. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. (d) Following the same protocol as in a, the membrane permeabilisation of both PAO1 and clinical isolate IT 2 was quantified after 2 h through ethidium homodimer fluorescence, measured on a GloMax® Discover (Ex = 520 nm, Em = 580–640 nm). Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗p < 0.01; ∗∗∗∗p < 0.0001. (e) To assess the potential of CoMiX in combination with the antibiotic amikacin, both PAO1 and clinical isolate IT 2 were incubated with 10% NHS in the presence or absence of 30 μg/mL of CoMiX or irrelevant control, as well as various sub-MIC concentrations of amikacin (2 μg/mL for PAO1, 10 μg/mL for clinical isolate IT 2) for 2 h at 37 °C. Bacteria were plated, and CFU were enumerated to assess bacterial viability. A synergy was admitted when the synergy coefficient (log(C) − log(SA) − log(SB) + log(SAB) < 0 (where C is CFU without treatment, SA is CFU with amikacin only, SB is CFU with CoMiX only, and SAB is CFU with both)), was negative (S). Data are presented as synergy coefficient calculated from the mean of three independent experiments (3 replicates per experiment).

Journal: eBioMedicine

Article Title: Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia

doi: 10.1016/j.ebiom.2025.105926

Figure Lengend Snippet: CoMiX enhance complement-mediated killing of P. aeruginosa and display synergy with amikacin. (a) Bacterial reference strain PAO1, and clinical isolate IT 2 were incubated without serum (w/o NHS), with 10% normal human serum (NHS) or with 10% decomplemented serum (ΔNHS) in the presence or absence of 30 μg/mL CoMiX or irrelevant control for 2 h at 37 °C. Bacteria were plated and CFU were enumerated to assess bacterial viability. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. (b) A mutated PAO1 bacterial strain with a luminescence-based reporter system (PAO1-Lux) was used in the same protocol to monitor in real-time bacterial growth. The luminescence of bacteria (RLU) was measured after 2 h of incubation on a POLARStar Omega microplate reader, as it is known that luminescence of bacteria correlates well with its concentration. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗∗∗p < 0.0001. (c) The complement potency of mouse serum (MS) and decomplemented MS (ΔMS) was assessed using the same protocol as in a. Bacteria were plated and CFU were enumerated to assess bacterial viability. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (2–3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. (d) Following the same protocol as in a, the membrane permeabilisation of both PAO1 and clinical isolate IT 2 was quantified after 2 h through ethidium homodimer fluorescence, measured on a GloMax® Discover (Ex = 520 nm, Em = 580–640 nm). Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments (3 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test. ∗∗p < 0.01; ∗∗∗∗p < 0.0001. (e) To assess the potential of CoMiX in combination with the antibiotic amikacin, both PAO1 and clinical isolate IT 2 were incubated with 10% NHS in the presence or absence of 30 μg/mL of CoMiX or irrelevant control, as well as various sub-MIC concentrations of amikacin (2 μg/mL for PAO1, 10 μg/mL for clinical isolate IT 2) for 2 h at 37 °C. Bacteria were plated, and CFU were enumerated to assess bacterial viability. A synergy was admitted when the synergy coefficient (log(C) − log(SA) − log(SB) + log(SAB) < 0 (where C is CFU without treatment, SA is CFU with amikacin only, SB is CFU with CoMiX only, and SAB is CFU with both)), was negative (S). Data are presented as synergy coefficient calculated from the mean of three independent experiments (3 replicates per experiment).

Article Snippet: P. aeruginosa strain serotype IATS O11 (33358TM), reference strain PAO1 (15692TM), and PAO1-GFP (15692GFPTM) were obtained from the American Type Culture Collection (ATCC, USA).

Techniques: Incubation, Control, Bacteria, Concentration Assay, Membrane, Fluorescence

CoMiX-Fc enhances significantly phagocytosis of P. aeruginosa by PBMCs-derived M1 macrophages and more importantly by Neutrophils-Like Cells, nevertheless, both CoMiX slightly improve NLCs-dependent antimicrobial activity against the bacteria. PMA-activated M1 macrophages, from four different healthy donors, were co-incubated with pHrodo-stained P. aeruginosa (PAO1) at a 12:1 bacteria-to-cell ratio with 10% NHS and in the presence or absence of 15 μg/mL CoMiX-Fc, CoMiX-FHR1 or CoMiX-irrelevant. Engulfment of bacteria was assessed after 30 min (left panels) and 1 h (right panels) by real-time Incucyte® microscope (a–c) . The percentage of pHrodo positive cells (a) and the intensity of pHrodo rationalised over the surface of cells and calculated as integrated intensity (b) were recorded. Data are presented as the mean values ± SEM. Results correspond to two independent experiments with macrophages from 4 healthy donors (three technical replicates per donor). Statistical analysis was performed using paired one-way ANOVA (to smooth inter-donor variability), followed by Tukey's post-hoc test: ∗p < 0.05; ∗∗p < 0.01. (c) Representative incucyte images for the phagocytosis induced by serum and CoMiX-Fc over time. (d) Fluorescence microscopy image obtained on a wide field Axio Observer Z1, and treated on ImageJ of phagocytosed P. aeruginosa bacteria by PBMCs-derived M1 macrophages in presence of 10% serum and 15 μg/mL CoMiX-Fc. Red = wheat germ agglutinin Alexa-647, staining carbohydates residues of macrophages membranes; green = CellTrace™ CFSE stained P. aeruginosa bacteria. Scale bar = 25 μm. P. aeruginosa PAO1 strain and PAO1-GFP strain were co-cultured with NLCs at a 10:1 bacteria-to-cell ratio, treated with 2% NHS and CoMiX (15 μg/mL) and incubated for 20 min at 37 °C under agitation (200 rpm). After washes and treatment with gentamicin to eliminate non-phagocytosed bacteria from the cells samples were (1) fixed and read by flow cytometry. (e) Gating of NLCs with FSC and SSC to eliminate cell debris and free bacteria from the analysis (left graph). Representative histogram describing the total population of NLCs, and composed of GFP negative cells and GFP positive cells (right graph). To assess phagocytosis, the percentage of GFP positive cells (f) and the mean fluorescence (g) were acquired. Data are presented as the mean values ± SEM. Results correspond to three pooled experiments (2 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: ∗∗∗∗p < 0.0001. (h) After washes and treatment with gentamicin, cells were also (2) lysed by Triton X-100, diluted in PBS and plated onto petri dishes. CFUs, corresponding to phagocytosed bacteria were counted in duplicates. Data are presented as the mean values ± SEM. Results correspond to three pooled independent experiments (2 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: ∗∗∗∗p < 0.0001. To assess NLCs-dependent killing, P. aeruginosa PAO1 strain at a MOI of 2:1 was co-cultured with NLCs, treated with 10% NHS and CoMiX (15 μg/mL) for 1 h, plated on petri dishes to count the final bacterial CFUs in duplicates (i) . Conditions which were not co-cultured with NLCs were used as control (100% cell survival). Results are expressed as surviving bacteria compared to bacterial growth under the same conditions in the absence of NLCs. Data are presented as the mean values ± SEM. Results correspond to three pooled independent experiments (2 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: ∗p < 0.05; ∗∗p < 0.01.

Journal: eBioMedicine

Article Title: Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia

doi: 10.1016/j.ebiom.2025.105926

Figure Lengend Snippet: CoMiX-Fc enhances significantly phagocytosis of P. aeruginosa by PBMCs-derived M1 macrophages and more importantly by Neutrophils-Like Cells, nevertheless, both CoMiX slightly improve NLCs-dependent antimicrobial activity against the bacteria. PMA-activated M1 macrophages, from four different healthy donors, were co-incubated with pHrodo-stained P. aeruginosa (PAO1) at a 12:1 bacteria-to-cell ratio with 10% NHS and in the presence or absence of 15 μg/mL CoMiX-Fc, CoMiX-FHR1 or CoMiX-irrelevant. Engulfment of bacteria was assessed after 30 min (left panels) and 1 h (right panels) by real-time Incucyte® microscope (a–c) . The percentage of pHrodo positive cells (a) and the intensity of pHrodo rationalised over the surface of cells and calculated as integrated intensity (b) were recorded. Data are presented as the mean values ± SEM. Results correspond to two independent experiments with macrophages from 4 healthy donors (three technical replicates per donor). Statistical analysis was performed using paired one-way ANOVA (to smooth inter-donor variability), followed by Tukey's post-hoc test: ∗p < 0.05; ∗∗p < 0.01. (c) Representative incucyte images for the phagocytosis induced by serum and CoMiX-Fc over time. (d) Fluorescence microscopy image obtained on a wide field Axio Observer Z1, and treated on ImageJ of phagocytosed P. aeruginosa bacteria by PBMCs-derived M1 macrophages in presence of 10% serum and 15 μg/mL CoMiX-Fc. Red = wheat germ agglutinin Alexa-647, staining carbohydates residues of macrophages membranes; green = CellTrace™ CFSE stained P. aeruginosa bacteria. Scale bar = 25 μm. P. aeruginosa PAO1 strain and PAO1-GFP strain were co-cultured with NLCs at a 10:1 bacteria-to-cell ratio, treated with 2% NHS and CoMiX (15 μg/mL) and incubated for 20 min at 37 °C under agitation (200 rpm). After washes and treatment with gentamicin to eliminate non-phagocytosed bacteria from the cells samples were (1) fixed and read by flow cytometry. (e) Gating of NLCs with FSC and SSC to eliminate cell debris and free bacteria from the analysis (left graph). Representative histogram describing the total population of NLCs, and composed of GFP negative cells and GFP positive cells (right graph). To assess phagocytosis, the percentage of GFP positive cells (f) and the mean fluorescence (g) were acquired. Data are presented as the mean values ± SEM. Results correspond to three pooled experiments (2 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: ∗∗∗∗p < 0.0001. (h) After washes and treatment with gentamicin, cells were also (2) lysed by Triton X-100, diluted in PBS and plated onto petri dishes. CFUs, corresponding to phagocytosed bacteria were counted in duplicates. Data are presented as the mean values ± SEM. Results correspond to three pooled independent experiments (2 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: ∗∗∗∗p < 0.0001. To assess NLCs-dependent killing, P. aeruginosa PAO1 strain at a MOI of 2:1 was co-cultured with NLCs, treated with 10% NHS and CoMiX (15 μg/mL) for 1 h, plated on petri dishes to count the final bacterial CFUs in duplicates (i) . Conditions which were not co-cultured with NLCs were used as control (100% cell survival). Results are expressed as surviving bacteria compared to bacterial growth under the same conditions in the absence of NLCs. Data are presented as the mean values ± SEM. Results correspond to three pooled independent experiments (2 replicates per experiment). Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test: ∗p < 0.05; ∗∗p < 0.01.

Article Snippet: P. aeruginosa strain serotype IATS O11 (33358TM), reference strain PAO1 (15692TM), and PAO1-GFP (15692GFPTM) were obtained from the American Type Culture Collection (ATCC, USA).

Techniques: Derivative Assay, Activity Assay, Bacteria, Incubation, Staining, Microscopy, Fluorescence, Cell Culture, Flow Cytometry, Control

Prophylactic treatment with anti-Psl CoMiX protects mice from lethal P. aeruginosa lung infection. (a) Eight-week-old female C57BL/6J mice were infected intranasal ( i.n. ) with a lethal dose (3 × 10 6 CFU) of luciferase-expressing PAO1 strain. Mice were treated with anti-Psl CoMiX-Fc, anti-Psl CoMiX-FHR1 or an irrelevant CoMiX control 3 h before and after intranasal infection with luciferase-positive P. aeruginosa PAO1. Survival (b) and body weight (c) were assessed daily for six days following infection. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments ( n = 8–16 mice per group). Statistical analysis was performed using the log-rank test (Mantel–Cox). ∗∗∗∗p < 0.0001. (d, e) Lung infection was assessed by visualising P. aeruginosa -associated luminescence emission in live animals at 24 h and 48 h p.i. One representative mouse image for the time-point 24 h and for each group is displayed. Data are presented as a percentage of mice with negative versus positive signal for bacteria. The data were analysed using a Chi-square test for direct comparisons between anti-Psl CoMiX and the irrelevant control (∗p < 0.05; ∗∗p < 0.01).

Journal: eBioMedicine

Article Title: Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia

doi: 10.1016/j.ebiom.2025.105926

Figure Lengend Snippet: Prophylactic treatment with anti-Psl CoMiX protects mice from lethal P. aeruginosa lung infection. (a) Eight-week-old female C57BL/6J mice were infected intranasal ( i.n. ) with a lethal dose (3 × 10 6 CFU) of luciferase-expressing PAO1 strain. Mice were treated with anti-Psl CoMiX-Fc, anti-Psl CoMiX-FHR1 or an irrelevant CoMiX control 3 h before and after intranasal infection with luciferase-positive P. aeruginosa PAO1. Survival (b) and body weight (c) were assessed daily for six days following infection. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments ( n = 8–16 mice per group). Statistical analysis was performed using the log-rank test (Mantel–Cox). ∗∗∗∗p < 0.0001. (d, e) Lung infection was assessed by visualising P. aeruginosa -associated luminescence emission in live animals at 24 h and 48 h p.i. One representative mouse image for the time-point 24 h and for each group is displayed. Data are presented as a percentage of mice with negative versus positive signal for bacteria. The data were analysed using a Chi-square test for direct comparisons between anti-Psl CoMiX and the irrelevant control (∗p < 0.05; ∗∗p < 0.01).

Article Snippet: P. aeruginosa strain serotype IATS O11 (33358TM), reference strain PAO1 (15692TM), and PAO1-GFP (15692GFPTM) were obtained from the American Type Culture Collection (ATCC, USA).

Techniques: Infection, Luciferase, Expressing, Control, Bacteria

CoMiX protect mice from acute lung infection of P. aeruginosa . (a) Eight-week-old female C57BL/6J mice were infected intranasal ( i.n. ) with a lethal dose (3 × 10 6 CFU) of luciferase-expressing PAO1 strain. Mice were treated 1 h later with 100 μg of CoMiX-Fc, CoMiX-FHR1 or an irrelevant CoMiX via i.n. administration. Survival (b) and body weight (c) were monitored for 7 days after infection. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments ( n = 16 mice per group). Statistical analysis was performed using the log-rank test (Mantel–Cox). ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. (d, e) Lung infection was assessed by visualising P. aeruginosa -associated luminescence emission in live animals at 24 h and 48 h p.i. One representative mouse image for the time-point 24 h and for each group is displayed. Data are presented as a percentage of mice with negative versus positive signal for bacteria. The data were analysed using a Chi-square test for direct comparisons between anti-Psl CoMiX and the irrelevant control (∗∗p < 0.01; ∗∗∗p < 0.001).

Journal: eBioMedicine

Article Title: Directed-complement killing of Pseudomonas aeruginosa protects against lethal pneumonia

doi: 10.1016/j.ebiom.2025.105926

Figure Lengend Snippet: CoMiX protect mice from acute lung infection of P. aeruginosa . (a) Eight-week-old female C57BL/6J mice were infected intranasal ( i.n. ) with a lethal dose (3 × 10 6 CFU) of luciferase-expressing PAO1 strain. Mice were treated 1 h later with 100 μg of CoMiX-Fc, CoMiX-FHR1 or an irrelevant CoMiX via i.n. administration. Survival (b) and body weight (c) were monitored for 7 days after infection. Data are presented as the mean values ± SEM. Results correspond to two pooled independent experiments ( n = 16 mice per group). Statistical analysis was performed using the log-rank test (Mantel–Cox). ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. (d, e) Lung infection was assessed by visualising P. aeruginosa -associated luminescence emission in live animals at 24 h and 48 h p.i. One representative mouse image for the time-point 24 h and for each group is displayed. Data are presented as a percentage of mice with negative versus positive signal for bacteria. The data were analysed using a Chi-square test for direct comparisons between anti-Psl CoMiX and the irrelevant control (∗∗p < 0.01; ∗∗∗p < 0.001).

Article Snippet: P. aeruginosa strain serotype IATS O11 (33358TM), reference strain PAO1 (15692TM), and PAO1-GFP (15692GFPTM) were obtained from the American Type Culture Collection (ATCC, USA).

Techniques: Infection, Luciferase, Expressing, Bacteria, Control